Last reviewed · How we verify
Toremifene; Anastrozole
Toremifene; Anastrozole is a Selective estrogen receptor modulator (SERM) + aromatase inhibitor (AI) Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved for Hormone receptor-positive breast cancer (metastatic or advanced).
This combination uses toremifene (a selective estrogen receptor modulator) and anastrozole (an aromatase inhibitor) to block estrogen signaling and production in hormone receptor-positive breast cancer.
Toremifene is a small molecule used in the treatment of breast cancer, specifically in postmenopausal women with HER2/Neu negative, invasive, or stage 0 breast cancer. Anastrozole is also used in the treatment of breast cancer, particularly in postmenopausal women, and is often compared to tamoxifen and toremifene in clinical trials.
At a glance
| Generic name | Toremifene; Anastrozole |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Selective estrogen receptor modulator (SERM) + aromatase inhibitor (AI) |
| Target | Estrogen receptor (ER); aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Toremifene acts as a selective estrogen receptor (ER) antagonist in breast tissue, blocking estrogen-driven proliferation of cancer cells. Anastrozole inhibits the aromatase enzyme, reducing peripheral conversion of androgens to estrogen, thereby lowering circulating estrogen levels. Together, they provide dual suppression of estrogen-dependent breast cancer growth through receptor antagonism and hormone depletion.
Approved indications
- Hormone receptor-positive breast cancer (metastatic or advanced)
Common side effects
- Hot flashes
- Vaginal bleeding/discharge
- Arthralgia
- Bone loss/osteoporosis
- Nausea
Key clinical trials
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial (PHASE3)
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy (PHASE2)
- Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) (PHASE2)
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer (PHASE2)
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) (PHASE3)
- Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
- Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Breast Cancer Treatment Based on Organ-like Culture
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toremifene; Anastrozole CI brief — competitive landscape report
- Toremifene; Anastrozole updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about Toremifene; Anastrozole
What is Toremifene; Anastrozole?
How does Toremifene; Anastrozole work?
What is Toremifene; Anastrozole used for?
Who makes Toremifene; Anastrozole?
What drug class is Toremifene; Anastrozole in?
What development phase is Toremifene; Anastrozole in?
What are the side effects of Toremifene; Anastrozole?
What does Toremifene; Anastrozole target?
Related
- Drug class: All Selective estrogen receptor modulator (SERM) + aromatase inhibitor (AI) drugs
- Target: All drugs targeting Estrogen receptor (ER); aromatase (CYP19A1)
- Manufacturer: Peking Union Medical College Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive breast cancer (metastatic or advanced)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing